Clinical Development
CT01681’s ability to safely modulate the cytokine response makes it an ideal solution to address inflammation across a pipeline of indications.
Download White PaperPipeline Expansion Opportunities
Multiple Indications Face CRS and ICANS Challenges
By effectively addressing CRS and ICANS and mitigating the inflammation in the TME, CTO1681 may improve the safety profile and efficacy of CAR T and TCE immunotherapies enabling them to expand into additional indications such as solid tumors and autoimmune disease.
Moreover, CTO1681 could also be utilized to treat other cytokine driven conditions such as asthma/COPD and atopic dermatitis. As such, it has the potential to improve the lives of a tremendous number of patients in a broad range of circumstances.
- CAR T and TCE in Solid Tumors
- CAR T and TCE in Autoimmune Diseases
- ASTHMA / COPD
- ATOPIC DERMATITIS
Rapid Clinical Development
Using CTO1681 Combined with CAR T in Oncology
Enrolling 1b/2a Clinical Trial
CytoAgents is conducting its Phase 1b/2a clinical trial to treat CRS in patients receiving CAR T-Cell therapy. Immunotherapies such as CAR T and TCE therapies trigger powerful immune responses to fight disease, which often induces CRS and ICANS. CTO1681’s ability to safely modulate the cytokine response while keeping the immune system functionally intact makes it an ideal CRS and ICANS prevention and treatment. Effective CRS and ICANS prevention and treatment will improve patient outcomes and expand patient access to these important, new treatment modalities.
Learn More- Fred Hutchinson Cancer Center
- University of Pittsburgh Medical Center
- Duke University Medical Center
- University California Irvine Medical Center
- Augusta University Medical Center
- Beth Israel Deaconess Medical Center
Clinician Perspectives
Addressing Unmet Needs in Oncology
Chairman, UPMC Hillman Cancer Center
Dr. Marks on CRS in
CAR T-Cell Patients
CTO1681 has demonstrated in multiple In Vivo and Ex Vivo models reduction of a broad range of cytokines driving CRS and ICANS. It reduces cytokine production regardless of the initial stimulus. CTO1681 does not overly suppress the immune system leaving it functionally intact and supporting the efficacy of CAR T and TCE therapies. It has demonstrated a superb safety profile even among vulnerable patients.
Dr. Frigault on CRS and ICANS Standard of Care
“Tocilizumab and steroids have proven not to be the ultimate solution for management of CRS and ICANS. New, safe therapeutics are still needed to keep patients out of the hospital/ICU and to reduce the financial strain on the healthcare system.”
Matthew Frigault, MD
Clinical Director, Cellular Therapy Service
Massachusetts General Hospital Cancer Center